Last reviewed · How we verify
low-dose tenecteplase intravenous thrombolysis
low-dose tenecteplase intravenous thrombolysis is a Fibrinolytic agent / Tissue plasminogen activator (tPA) Small molecule drug developed by Southwest Hospital, China. It is currently FDA-approved for Acute ischemic stroke within therapeutic window.
Low-dose tenecteplase is a fibrin-specific thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots in acute ischemic stroke.
Low-dose tenecteplase is a fibrin-specific thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots in acute ischemic stroke. Used for Acute ischemic stroke within therapeutic window.
At a glance
| Generic name | low-dose tenecteplase intravenous thrombolysis |
|---|---|
| Sponsor | Southwest Hospital, China |
| Drug class | Fibrinolytic agent / Tissue plasminogen activator (tPA) |
| Target | Plasminogen / Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Neurology |
| Phase | FDA-approved |
Mechanism of action
Tenecteplase is a tissue plasminogen activator (tPA) variant engineered for improved fibrin specificity and longer half-life compared to alteplase. At reduced doses, it activates the fibrinolytic cascade to break down thrombi while potentially reducing systemic bleeding complications. Low-dose regimens aim to maintain efficacy in clot lysis while improving the safety profile in acute stroke management.
Approved indications
- Acute ischemic stroke within therapeutic window
Common side effects
- Intracranial hemorrhage
- Systemic bleeding
- Angioedema
- Reperfusion injury
Key clinical trials
- Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients (PHASE4)
- ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 (PHASE3)
- Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits (PHASE4)
- A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (PHASE3)
- ACT-GLOBAL Adaptive Platform Trial for Stroke (PHASE3)
- CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low-dose tenecteplase intravenous thrombolysis CI brief — competitive landscape report
- low-dose tenecteplase intravenous thrombolysis updates RSS · CI watch RSS
- Southwest Hospital, China portfolio CI
Frequently asked questions about low-dose tenecteplase intravenous thrombolysis
What is low-dose tenecteplase intravenous thrombolysis?
How does low-dose tenecteplase intravenous thrombolysis work?
What is low-dose tenecteplase intravenous thrombolysis used for?
Who makes low-dose tenecteplase intravenous thrombolysis?
What drug class is low-dose tenecteplase intravenous thrombolysis in?
What development phase is low-dose tenecteplase intravenous thrombolysis in?
What are the side effects of low-dose tenecteplase intravenous thrombolysis?
What does low-dose tenecteplase intravenous thrombolysis target?
Related
- Drug class: All Fibrinolytic agent / Tissue plasminogen activator (tPA) drugs
- Target: All drugs targeting Plasminogen / Fibrin
- Manufacturer: Southwest Hospital, China — full pipeline
- Therapeutic area: All drugs in Cardiovascular / Neurology
- Indication: Drugs for Acute ischemic stroke within therapeutic window
- Compare: low-dose tenecteplase intravenous thrombolysis vs similar drugs
- Pricing: low-dose tenecteplase intravenous thrombolysis cost, discount & access